Journal article
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
- Abstract:
-
BACKGROUND: Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8(+) T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses. METHODS: From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) enco...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 438.2KB, Terms of use)
-
- Publisher copy:
- 10.1093/infdis/jir850
Authors
Funding
Bibliographic Details
- Publisher:
- Oxford University Press
- Journal:
- Journal of infectious diseases More from this journal
- Volume:
- 205
- Issue:
- 5
- Pages:
- 772-781
- Publication date:
- 2012-03-01
- DOI:
- EISSN:
-
1537-6613
- ISSN:
-
0022-1899
Item Description
- Language:
-
English
- Keywords:
- UUID:
-
uuid:bb773bd0-2a3f-49d7-aa9c-592b20127387
- Local pid:
-
pubs:245860
- Source identifiers:
-
245860
- Deposit date:
-
2012-12-19
Terms of use
- Copyright holder:
- O’Hara et al
- Copyright date:
- 2012
- Notes:
- Copyright © 2012 O’Hara et al. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record